Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 9601–9650 of 18437
On June 12, 2023, Zikang Wu as the sole director of the Company, appointed Zikang Wu as Chief Executive Officer, effective June 12, 2023.
On June 12, 2023, effective immediately, the following officers and directors submitted the resignation of their respective offices: Simon Cottle, as director and Chief Executive Officer, Patrick Hargutt, as director and Chief Financial Officer, and each of James Brooks, Greg Caswill, Robert Piconi, Xavier Flinois and Elizabeth Weymouth as directors of the Company.
On June 12, 2023, effective immediately, the following officers and directors submitted the resignation of their respective offices: Simon Cottle, as director and Chief Executive Officer, Patrick Hargutt, as director and Chief Financial Officer, and each of James Brooks, Greg Caswill, Robert Piconi, Xavier Flinois and Elizabeth Weymouth as directors of the Company.
Marathon Digital Holdings, Inc. (the “Company”) appointed Salman Khan as its new Chief Financial Officer, effective as of June 14, 2023.
On June 12, 2023, George Chi was terminated for cause as an employee and Chief Financial Officer of OncoSec Medical Incorporated (the “Company”), effective immediately.
In addition to his resignation from the Company’s Board of Directors, Dr. Arch tendered his resignation as the Company’s President and Chief Executive Officer effective on June 14, 2023
On June 9, 2023, Eric Schmidt, Ph.D., the Chief Financial Officer, principal financial officer and principal accounting officer of Allogene Therapeutics, Inc. (the “Company”), notified the Company of his decision to resign, effective at the close of business on August 2, 2023, to spend more time with his family.
the Board appointed Daniel Virnich, the Company’s current President, as Chief Executive Officer effective as of June 30, 2023
On June 11, 2023, the Board of Directors (the “Board”) of Illumina, Inc. (the “Company”) accepted the resignation of Francis deSouza, which Mr. deSouza submitted to the Board on June 8, 2023, as Chief Executive Officer and as a director of the Company, effective immediately
the Board appointed Charles Dadswell, the Company’s current Senior Vice President and General Counsel, to serve as interim Chief Executive Officer, effective immediately
the Board appointed Guy Gecht, who has served as an independent member of Board, member of the Audit Committee of the Board, and member and Chairperson of its Technology and Innovation Committee, as Interim Chief Executive Officer of Logitech, effective immediately.
Bracken Darrell resigned from his position as the President and Chief Executive Officer of Logitech International S.A.
Beatriz Blanco would be ending her employment as President of and Chief Executive Officer of the Company. Ms. Blanco’s role as President and her involvement in the daily operations of the company were mutually terminated effective June 8, 2023
the Company entered into an Employment Agreement (the “Employment Agreement”) with Chris Jones, age 49, to serve as Chief Financial Officer of the Company, effective July 10, 2023
Michael Rabinovitch, Chief Financial Officer of BurgerFi International, Inc., a Delaware corporation (the “Company”), notified the Company that he is resigning from his positions with the Company effective no later than July 31, 2023
Brian Drazba’s employment as the CFO of the Company will terminate as of the closing date of the Merger, and in any event no later than September 1, 2023.
Christopher E. Jones, Odyssey’s chief financial officer, has resigned from the company effective July 7, 2023, to pursue another opportunity.
the Bank entered into an employment agreement, effective June 26, 2023 (the "Employment Agreement") with Jennings 'Jay' Walker as Chief Financial Officer.
Mark Murray intends to retire as the Company's President and Chief Executive Officer, effective June 23, 2023
the Board of Directors (the "Board") of the Company had appointed David Knight, age 59, to succeed Mr. Murray as the Company's President and Chief Executive Officer, effective June 23, 2023
appointed Chris Rivera, age 44, as the Company’s Interim Chief Financial Officer and as the Company’s Principal Financial Officer during Ms. Chan’s parental leave, effective June 26, 2023.
appointed Patty Chan as the Company’s Chief Financial Officer, effective June 12, 2023.
The following officer appointments for the Company are effective immediately and the officers shall hold such positions until their earlier resignation, removal or death, or until their successor is duly appointed and qualified. Ross Sklar Chief Executive Officer, President Darin Brown Chief Operating Officer, Secretary David Dreyer Chief Marketing Officer Kevin Zaccardi Interim-Chief Financial Officer, Treasurer
The following officer appointments for the Company are effective immediately and the officers shall hold such positions until their earlier resignation, removal or death, or until their successor is duly appointed and qualified. Ross Sklar Chief Executive Officer, President Darin Brown Chief Operating Officer, Secretary David Dreyer Chief Marketing Officer Kevin Zaccardi Interim-Chief Financial Officer, Treasurer
John Butler, the Company’s President and Chief Executive Officer, will act as interim principal financial officer and principal accounting officer from the Transition Date until the Effective Date.
On June 12, 2023 , the Company announced that Ellen Snow will succeed Mr. Spellman as the Company’s Senior Vice President, Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer, effective July 17, 2023 (the “Effective Date”).
On June 9, 2023, David A. Spellman, Senior Vice President, Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer of Akebia Therapeutics, Inc. (the “Company”), notified the Company of his intent to resign.
On June 6, 2023, Patrick J. Guido notified Chico’s FAS, Inc. (the “Company”) of his decision to resign from the Company as Executive Vice President and Chief Financial Officer, to accept a position at another company where he can be located closer to his family.
Mr. Guido will be succeeded by David M. Oliver, who has been appointed Executive Vice President, Chief Financial Officer and Chief Accounting Officer of the Company, effective June 24, 2023.
On June 12, 2023, Michael F. Carotenuto, Executive Vice President, Chief Financial Officer, Treasurer and Corporate Secretary of Cambridge Bancorp (the “Company”) and Chief Financial Officer of Cambridge Trust (the “Bank”) notified the Company of his decision to pursue other career opportunities and resign from his roles at the Company and the Bank.
Mr. Joseph P. Sapienza, the Bank’s Controller, is expected to be named Interim CFO as the Company performs a search for Mr. Carotenuto’s replacement.
On June 6, 2023, Daniel Rogers notified the board of directors of Newcourt Acquisition Corp (the “Company”) that he has resigned from his position as Chief Financial Officer the Company, effective June 7, 2023.
On June 12, 2023, Kiromic BioPharma, Inc. (the "Company") appointed Brian Hungerford as interim Chief Financial Officer of the Company.
Mr. Baobing He, the Chief Executive Officer and Director of the Company, to be appointed as the Chief Financial Officer of the Company
Ms. Maggie Torres resigned as Interim Chief Financial Officer and Interim Treasurer of the Company and moved to the role of Director of Accounting Projects.
has appointed Dennis C. Schemm (age 57) as the Company’s Chief Financial Officer and Treasurer, effective as of June 12, 2023
Mr. Adams is expected to continue to serve as CEO until his successor joins the Company, at which time Mr. Adams will resign from the Company’s Board of Directors and will transition to non-executive employment with the Company as a special advisor to assist the CEO successor with transition matters for six months.
Effective June 6, 2023, Mr. Gregory Downey was dismissed as the Company’s Chief Financial Officer.
On June 11, 2023, Brad Hively provided notice of his resignation as Chief Executive Officer of The Oncology Institute, Inc. (the “Company”), effective June 30, 2023 (the “Effective Date”).
Effective as of June 30, 2023, the Board appointed Daniel Virnich, the Company’s current President, as Chief Executive Officer
On June 6, 2023, Michelle M. Harrison, Senior Vice President, Finance and Treasurer of the Company notified the Company of her decision to retire after more than 23 years of service with the Company.
In connection with Ms. Harrison's retirement, Peter A. Trpkovski, who is currently serving as Vice President, Finance and Investor Relations of the Company, will be promoted to the role of Senior Vice President, Finance and Treasurer, effective July 1, 2023.
appointed Paul H. Pickle to serve as the Company’s President and Chief Executive Officer effective as of a date, after June 8, 2023 and not later than June 30, 2023, to be mutually agreed between Mr. Pickle and the Chair of the Board (with Mr. Pickle’s first day of employment in such capacity, the “Transition Date”). On June 7, 2023, Mr. Pickle and the Chair of the Board agreed that the Transition Date will be June 30, 2023.
Mohan Maheswaran’s retirement as the Company’s President and Chief Executive Officer, and as a member of the Board, will be effective June 29, 2023.
In connection with the termination of his employment with the Company, effective May 15, 2023, Mr. Remondi will be provided with severance payments and benefits in accordance with the Severance Plan
On March 2, 2023, Oncocyte Corporation (the “Company”) issued a press release announcing that Joshua Riggs, the Interim Chief Executive Officer of the Company, was appointed the Chief Executive Officer of the Company, effective February 24, 2023
who resigned from his position as Chief Financial Officer and Chief Accounting Officer (as previously disclosed in the Company’s Current Report on Form 8-K filed on March 24, 2023), effective as of June 1, 2023.
the Company announced that Harsha V. Agadi ceased to serve as Interim Chief Executive Officer of the Company, also effective as of June 6, 2023, but will remain on the Board and assume the role of Non-Executive Chairman effective as of June 8, 2023.
the Board of Directors of the Company (the “Board”) has appointed Dr. Ryan Ezell, the Company’s existing President, to serve as its Chief Executive Officer, effective as of June 6, 2023.
the board of directors of the Company (the “Board”) appointed Mr. Andrew Taylor, age 52, as Chief Financial Officer of the Company to succeed Mr. Kaswan, effective as of the Separation Effective Date.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.